Dopamine receptor agonists in the therapy of Parkinson’s disease

  title={Dopamine receptor agonists in the therapy of Parkinson’s disease},
  author={Paul Foley and Manfred Gerlach and Kay L Double and Peter Franz Riederer},
  journal={Journal of Neural Transmission},
Forty years after its introduction by Birkmayer and Hornykiewicz (1961), L-DOPA-based therapy of Parkinson’s disease remains the central pillar in the management of the disorder. Nevertheless, it is not unproblematic, and dopamine receptor agonists play increasingly important roles in antiparkinsonian therapy. Pharmacological and pharmacokinetic properties of these agents are briefly reviewed and followed by a detailed summary of available literature concerning controlled trials in Parkinson’s… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-6 of 6 citations


Publications referenced by this paper.
Showing 1-10 of 131 references

Sleep attacks, daytime

  • S Paus, HM Brecht, J K€oster, G Seeger, T Klockgether, U W€ullner
  • review. Mov Disord
  • 2003
Highly Influential
3 Excerpts

Regional Drug Information Service (1999) New drugs in Parkinson’s disease: cabergoline, pramipexole, ropinirole, entacapone

  • South Thames
  • Therapeutic Rev,
  • 1999
Highly Influential
3 Excerpts

Der L-3,4-Dioxyphenylalanin (1⁄4DOPA)-Effekt bei der

  • W Birkmayer, O Hornykiewicz
  • 1961
Highly Influential
3 Excerpts